Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Fig. 2

Neoadjuvant therapy-induced changes of blood lymphocyte subsets and ratio of Tregs to CD4+ T cells. PBMCs before neoadjuvant treatment (baseline) and after treatment were analyzed. a. Changes of ratio of Tregs to CD4+ T cells after neoadjuvant endocrine therapy (NET) and neoadjuvant chemotherapy (NAC). b. Changes of percentage of CD8+ T cells among PBMCs after NET and NAC. c. Changes of percentage of B cells among PBMCs after NET and NAC. d. Changes of percentage of CD8+ NKT cells among PBMCs after NET and NAC. Statistical analyses were performed by Wilcoxon matched-pairs signed rank test and P < 0.05 was considered statistically significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us